Annovis Bio, Inc. (ANVS)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 11.49 |
| Open | 11.57 |
| Bid | 11.68 x 1200 |
| Ask | 11.74 x 800 |
| Day's range | 11.44 - 12.34 |
| 52-week range | 5.42 - 22.49 |
| Volume | |
| Avg. volume | 241,812 |
| Market cap | 130.814M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.23 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.40 |
ZacksVertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
ZacksVertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
ZacksBio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
© 2024 Yahoo. All rights reserved.